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Abstract: Genetic studies have identified associations between gene mutations and clear cell 
renal cell carcinoma (ccRCC). Since the complete gene mutational landscape cannot be 
characterized through biopsy and sequencing assays for each patient, non-invasive tools are 
needed to determine the mutation status for tumors. Radiogenomics may be an attractive 
alternative tool to identify disease genomics by analyzing amounts of features extracted from 
medical images. Most current radiogenomics predictive models are built based on a single 
classifier and trained through a single objective. However, since many classifiers are available, 
selecting an optimal model is challenging. On the other hand, a single objective may not be a 
good measure to guide model training. We proposed a new multi-classifier multi-objective 
(MCMO) radiogenomics predictive model. To obtain more reliable prediction results, 
similarity-based sensitivity and specificity were defined and considered as the two objective 
functions simultaneously during training. To take advantage of different classifiers, the 
evidential reasoning (ER) approach was used for fusing the output of each classifier. 
Additionally, a new similarity-based multi-objective optimization algorithm (SMO) was 
developed for training the MCMO to predict ccRCC related gene mutations (VHL, PBRM1 and 
BAP1) using quantitative CT features. Using the proposed MCMO model, we achieved a 
predictive area under the receiver operating characteristic curve (AUC) over 0.85 for VHL, 
PBRM1 and BAP1 genes with balanced sensitivity and specificity. Furthermore, MCMO 
outperformed all the individual classifiers, and yielded more reliable results than other 
optimization algorithms and commonly used fusion strategies. 
1. Introduction 
Kidney cancer, most predominantly, renal cell carcinoma (RCC) remains one of the most 
common renal malignancies with 63,990 new cases expected to be diagnosed and with 14,400 
deaths in the United States in 2017 (Siegel et al, 2017). Clear cell RCC (ccRCC) is the most 
abundant (~75%) subtype of RCC and the most likely to metastasize outside the kidney (Motzer 
et al, 2002). Most cases of ccRCC present with somatic (or germline) inactivating mutations in 
the von Hippel–Lindau tumor suppressor (VHL) gene, which are generally absent in other 
cancers (Gnarra et al, 1994; Varela et al, 2011; Guo et al, 2012; Cancer Genome Atlas Research 
Network, 2013). Several other mutations in genes involved in regulating chromatin states, 
including those in the BRCA1-associated protein 1 (BAP1), polybromo 1 (PBRM1), SET domain 
containing 2 (SETD2), and lysine (K)-specific demethylase 5C (KDM5C), were recently identified 
(Dalgliesh et al, 2010; Varela et al, 2011; Duns et al, 2010; Peña-Llopis et al, 2012). Mutations 
in BAP1 and SETD2 were found to be associated with advanced stage and poor outcome 
(Cancer Genome Atlas Research Network, 2013; Hakimi et al, 2013; Kapur et al, 2013). The 
genes mutated within a tumor can be used as biomarkers and may help with prognosis, 
treatment selection, and treatment response prediction. However, inter- and intra-tumoral 
heterogeneity in gene mutations has previously been described in ccRCC (Gerlinger et al, 2012, 
2014; McGranahan and Swanton, 2015). As ccRCC metastasizes, additional gene mutations 
accumulate. Because the complete gene mutational landscape is hard to be characterized for 
each patient through biopsy and sequencing assays, a non-invasive tool would be useful to 
identify the mutations within the tumor. 
Radiogenomics (Rutman and Kuo, 2009; Jaffe, 2012; Kuo and Jamshidi, 2014; Karlo et al, 
2014; Shinagare et al, 2015; Sala et al, 2017), an integrated approach that combines radiology 
and genomics, is based on extracting and analyzing amounts of data from medical images and 
clinical information by high-throughput computing. Therefore, radiogenomics is a promising 
solution for predicting gene mutation in ccRCC. Contrast-enhanced computed tomography (CT) 
is commonly used to diagnose and characterize renal masses, monitor growth in 
pathologically-proven RCC undergoing active surveillance, assess RCC location and extent, and 
determine stage and treatment response (Stewartmerrill et al, 2015; Motzer et al, 2017). 
Furthermore, the diagnostic standard of reference has expanded to the genomic level and has 
led to the attempt to use imaging as a noninvasive determinant of mutational status (Reznek, 
2004; Powles and Albers, 2012; Carles et al, 2012; Kuo and Yamamoto, 2011). Therefore, a CT 
based radiogeneomics predictive model would be helpful.  
In recent years, researchers have investigated predictable and systematic associations 
between imaging features and underlying molecular and genomic alterations in different 
cancers. Yamamoto et al (2012) carried out a radiogenomic analysis of breast cancer with MRI, 
a novel approach that may help reveal the underlying molecular biology of breast cancers. 
Gevaert et al (2017) used CT image features to predict the mutation status of EGFR in non–
small cell lung cancer (NSCLC). Aerts et al (2014) revealed that a prognostic radiomic feature 
set, capturing intra-tumor heterogeneity, is associated with underlying gene-expression 
patterns. One study reported associations between CT features of 58 ccRCCs and the 
underlying karyotype (Sauk et al, 2011). Others studied the association between CT imaging 
features and mutational status of ccRCC (Karlo et al, 2014; Shinagare et al, 2015). For example, 
the BAP1 mutation was associated with ill-defined tumor margins and calcification (Shinagare 
et al, 2015).  
By quantitatively analyzing large amounts of information from medical images, 
radiogenomics holds great potential to predict gene mutation. However, several challenges 
need to be addressed to build an optimal predictive model. First, a single classifier is typically 
used to build a radiogenomics predictive model. Aerts et al (2014) used the Cox proportional 
hazards regression model to predict survival in patients with lung and head-and-neck cancer. 
Other researchers tested different types of classifiers and chose one or two “preferred” ones 
for specific applications. Valdes et al (2016) evaluated three different classifiers, including 
decision trees, random forests, and RUSBoost, to predict radiation pneumonitis in patients 
with stage I NSCLC treated with stereotactic body radiation therapy (SBRT). Higher accuracy 
was achieved when the RUSBoost algorithm was used with regularization. These findings 
indicate how difficult it is to select a “preferred” classifier for a specific application. Instead of 
trying to find the most suitable classifier for a particular application, a model that combines 
multiple classifiers can fully use information from different classifiers to improve accuracy in 
radiogenomics. Second, most current radiogenomics models adopt a single objective function 
(e.g. accuracy, AUC), which may not be a good measure for building the predictive model, 
especially when positive and negative cases are imbalanced. To overcome the disadvantages 
of using a single classifier and a single objective function, we sought to develop a multi-
classifier multi-objective (MCMO) radiogenomics model predict most mutations in most 
commonly mutated genes in ccRCC. In MCMO, multiple classifiers are used for building the 
model and a multi-objective optimization algorithm is used for training the model.  
 
2. Materials and Methods 
2.1 Data 
2.1.1 Patients. We conducted an institutional review board-approved, Health Insurance 
Portability and Accountability Act-compliant (HIPAA), retrospective study including 57 ccRCC 
patients from two independent cohorts. The first cohort consisted of 33 patients (median age 
62 years, range 28–83) from the University of Texas Southwestern Medical Center (UTSW). The 
other cohort consisted of 24 patients (median age 59 years, range 26–74) from The Cancer 
Genome Atlas Kidney Renal Clear Cell Carcinoma (TCGA-KIRC) data collection. The TCGA-KIRC 
data collection is part of The Cancer Genome Atlas (TCGA), an ongoing project funded by the 
National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI), 
which created an atlas of genetic changes related to more than 20 tumor types, including 
ccRCC. Clinical, genetic, and pathological data reside in the TCGA data portal, and radiological 
data is stored in The Cancer Imaging Archive (TCIA). Both TCGA and TCIA are accessible for 
public download (Smith et al, 2016; Clark et al, 2013). 
All 57 patients fulfilled the following criteria: (a) histopathologic diagnosis of ccRCC and 
exome sequencing, including information on VHL, PBRM1, and BAP1 gene mutations, 
considered as frequent mutations in ccRCC; (b) availability of images from a pretreatment 
contrast-enhanced CT including a corticomedullary phase. For each gene, the numbers of 
patients with mutation and without mutation are listed (table 1). 
2.1.2 CT Image features. CT images from UTSW were acquired by GE LightSpeed VCT (GE 
Healthcare, Waukesha, WI) or TOSHIBA Aquilion ONE (Canon Medical Systems USA, Tustin, CA). 
CT image size was 512 × 512 with a pixel size of 0.7~0.9 mm, and slice thickness was 3 or 5mm. 
Table 1. Number of patients 
 VHL PBRM1 BAP1 
Mutation Non-mutation Mutation Non-mutation Mutation Non-mutation 
UTSW 26 7 19 14 5 28 
TCGA 10 14 3 21 2 22 
Total 36 21 22 35 7 50 
CT images from TCIA were acquired by the SIEMENS Sensation 64 / Definition AS+ (Siemens 
Medical Solution, Malvern, PA), Philips Brilliance 64 (Philips Healthcare, Andover, MA), or GE 
LightSpeed VCT. CT image size was 512 × 512 with a pixel size of 0.7~1 mm and slice thickness 
was 1.25 or 5 mm. 
The primary tumor contour was delineated by a radiation oncologist with 4 years of 
experience and reviewed by a radiation oncologist with 9 years of experience. Contrast 
enhanced CT images acquired during the corticomedullary phase were used in all 57 cases for 
image analysis. A region of interest (ROI) was drawn along the outer contour of the mass using 
the Velocity 3.2.0 software excluding adjacent tissues (e.g. renal parenchyma, peri-renal fat) 
(figure 1). 
We resampled all images of the same slice thickness at 5mm. We only considered primary 
tumors and defined 43 quantitative image features describing tumor characteristics, including 
13 geometry features, 9 intensity features, and 21 texture features (table 2). Geometry 
features describing tumor shape and size were calculated according to the actual pixel size. 
Features Size_X, Size_Y and Size_Z (table 2) describe the tumor size along the X, Y, and Z axes 
of the digital imaging and communications in medicine (DICOM) coordinate system (figure 2 
(a)). The shape and location of the tumors differed from patient to patient. To intuitively 
describe the size of the tumor, a principal component analysis (PCA) was applied to the tumor 
contour points to transform the data into a new coordinate system. Size_P1 is the maximum 3 
dimensional diameter of the tumor, measured as the largest pairwise Euclidean distance 
between the voxels on the surface of the tumor volume; size_P2 and size_P3 are the tumor 
size along the directions orthogonal to the direction of maximum size (figure 2(b)). 
 
         
(a)                               (b) 
Figure 1. Tumor contour of ccRCC investigated in this study. (a) one case from UTSW. (b) one case from 
TCIA. 
 
 
 
Table 2. Quantitative CT Image Features 
Geometry features Intensity features Texture features 
Volume Minimum  Auto correlation 
Size_X Maximum Contrast 
Size_Y Mean Correlation 
Size_Z Median Cluster prominence 
Size_P1 Sum Cluster shade 
Size_P2 Variance Dissimilarity 
Size_P3 Standard deviation Energy 
Roundness Skewness Entropy 
Surface area Kurtosis Homogeneity 
Compactness_1   Maximum probability 
Compactness_2   Variance 
Spherical disproportion  Sum average 
Surface to volume ratio  Sum variance 
  Sum entropy 
  Difference variance 
  Difference entropy 
  Information measure of correlation_1 
  Information measure of correlation_2 
  Inverse difference 
  Inverse difference normalized 
  Inverse difference moment normalized 
 
 
(a)                                (b) 
Figure 2. Coordinate systems. (a) The digital imaging and communications in medicine (DICOM) 
coordinate system. (b) Illustration of the transformation of the DICOM coordinate system into the PCA 
coordinate system. 
 
Intensity features are first-order statistics that describe the distribution of the voxel 
intensities within the tumor on the CT image through commonly used basic metrics (Aerts et 
al, 2014). Intensity features provide information related to the gray-level distribution of the 
image; however, they do not provide any information on the relative position of the various 
gray levels over the image. Therefore, we included textural features that either describe the 
patterns or the spatial distribution of voxel intensities, which were calculated from the gray 
level co-occurrence matrix (GLCM) (Haralick et al, 1973). Texture matrix representation 
requires the voxel intensity values within the volume of interest to be discretized. In this work, 
voxel intensities were resampled into 64 equally spaced bins using a bin-width of 25 
Hounsfield Units (HU). The detailed methodology of extracting intensity and texture features 
was previously described by Aerts et al (2014) (supplementary document). The calculated 
features of the 57 patients were normalized using the Z-scores method (Cheadle et al, 2003). 
2.2. MCMO predictive model 
2.2.1 Evidential reasoning based classifier fusion The evidential reasoning (ER) approach was 
used for fusing the individual classifier probability output (Yang and Xu, 2002, 2013). Our study 
is a binary classification problem (mutation or non-mutation). Assuming there are 𝑀 
classifiers, for a test sample, the output probability of each classifier is denoted by 𝑃𝑖 =
{𝑃𝑖
1, 𝑃𝑖
2}, 𝑖 = 1, ⋯ , 𝑀, which satisfies: 
𝑃𝑖
1 + 𝑃𝑖
2 = 1.                               (1) 
Where 𝑃𝑖
1  is output probability of gene mutation and 𝑃𝑖
2  is output probability of non- 
mutation. Assume the relative weight of each classifier as 𝒘 = {𝑤1, 𝑤2, ⋯ , 𝑤𝑀} , which 
satisfies the following constraint: 
∑ 𝑤𝑖
𝑀
𝑖=1 = 1, 0 ≤ 𝑤𝑖 ≤ 1.                          (2) 
The final output probabilities 𝑃𝑓𝑖𝑛
𝑗 , 𝑗 = 1,2 are obtained by classifier fusion through the ER 
approach (Yang and Xu, 2002, 2013):  
 𝑃𝑓𝑖𝑛
𝑗 = 𝐸𝑅(𝑃𝑖
𝑗, 𝑤𝑖), 𝑖 = 1, ⋯ , 𝑀, 𝑗 = 1,2,                  (3) 
 
where 𝐸𝑅 represents the ER analytic algorithm (Wang et al, 2006), which is calculated as: 
𝑃𝑓𝑖𝑛
𝑗 =
𝜇×[∏ (𝑤𝑖𝑃𝑖
𝑗
+1−𝜔𝑖)−∏ (1−𝑤𝑖)
𝑀
𝑖=1
𝑀
𝑖=1 ]
1−𝜇×[∏ (1−𝑤𝑖)
𝑀
𝑖=1 ]
, 𝑗 = 1,2,             (4) 
where 𝜇 is calculated as: 
𝜇 = [∑ ∏ (𝑤𝑖𝑃𝑖
𝑗
+ 1 − 𝑤𝑖) − ∏ (1 − 𝑤𝑖)
𝑀
𝑖=1
𝑀
𝑖=1
2
𝑗=1 ]
−1
.          (5) 
   For a binary classification problem, if 𝑃𝑓𝑖𝑛
1 > 𝑃𝑓𝑖𝑛
2 , the test sample belongs to class 1; if 
𝑃𝑓𝑖𝑛
1 < 𝑃𝑓𝑖𝑛
2 , the test sample belongs to class 2; if 𝑃𝑓𝑖𝑛
1 = 𝑃𝑓𝑖𝑛
2 , the test sample belong to either 
class. In this study, We sought to predict either the presence or absence of gene mutation. 
Therefore, if 𝑃𝑓𝑖𝑛
1 > 𝑃𝑓𝑖𝑛
2 , we considered the test sample had mutation; if 𝑃𝑓𝑖𝑛
1 ≤ 𝑃𝑓𝑖𝑛
2 , we 
considered the test sample had non-mutation.  
 
2.2.2 Reliable outcome prediction based on output probability similarity To obtain more 
reliable predictive results, reliable outcome prediction (RCP) is proposed and defined as 
maximize the similarity between predicted output probability and true label vector. For 
example, we assume two models that predict the VHL gene mutation with the label vector [1, 
0]. Model A has prediction probabilities (0.8, 0.2) (the probability of mutation is 0.8, the 
probability of non-mutation is 0.2, and the threshold is 0.5), and model B has prediction 
probabilities (0.55, 0.45). As 0.8 is closer to 1 than 0.55, the result of model A is more reliable 
than that of model B. In other words, the similarity between the probability output of model 
A and the label vector is higher than those observed for model B, which means model A is 
more reliable than model B in this prediction.  
In RCP, the aim is to maximize the similarity between predicted output probability and true 
label vector T while training the single classifier model and weights. For a training sample, its 
label vector is denoted by 𝑻 = [𝑇1, 𝑇2]. 𝑇 is a binary vector, 𝑻 = [1,0]  (mutation) or 𝑻 =
[0,1] (non-mutation). Assuming that the predictive model has q parameters denoted by 𝑹 =
{𝑅1, 𝑅2, ⋯ , 𝑅𝑞}, the objective function is expressed as: 
𝑓 = 𝑚𝑎𝑥
            𝒘,𝑹
∑ 𝑠𝑖𝑚(𝑃𝑘 , 𝑇𝑘)𝐾𝑘=1 ,                         (6) 
where 𝐾  represents the number of training samples and 𝑠𝑖𝑚 is the similarity measure. 
Since the above problem can be considered as the similarity of probability distribution and the 
dice coefficient (Sung-Hyuk, 2007) is effective for measuring similarity, it is used here: 
𝑠𝑖𝑚(𝑃𝑘 , 𝑇𝑘) =
2 ∑ 𝑃𝑗
𝑘𝑇𝑗
𝑘2
𝑗=1
∑ (𝑃𝑗
𝑘)
2
+∑ (𝑇𝑗
𝑘)
2
2
𝑗=1
2
𝑗=1
.                      (7) 
Since a single objective may not be a good measure when the training dataset is imbalanced, 
we consider sensitivity and specificity simultaneously as a better solution as follows: 
𝑓𝑠𝑒𝑛 =
𝑇𝑃
𝑇𝑃+𝐹𝑁 
,   𝑓𝑠𝑝𝑒 =
𝑇𝑁
𝑇𝑁+𝐹𝑃 
,                       (8) 
where 𝑇𝑃 is the number of true positives, 𝑇𝑁 is the number of true negatives, 𝐹𝑃 is the 
number of false positives, and 𝐹𝑁 is the number of false negatives. In our previous study, 
𝑓𝑠𝑒𝑛 and 𝑓𝑠𝑝𝑒 were both considered as objective functions (Zhou et al, 2017). 
However, 𝑓𝑠𝑒𝑛  and 𝑓𝑠𝑝𝑒  are label based measures, while we sought to maximize the 
similarity of probability output and the true label vector. Therefore, we defined the new 
similarity-based sensitivity and specificity denoted by 𝑓𝑠𝑖𝑚_𝑠𝑒𝑛 and 𝑓𝑠𝑖𝑚_𝑠𝑝𝑒 , respectively. 
Assume that {𝑃𝑡𝑝
1 , 𝑃𝑡𝑝
2 , ⋯ , 𝑃𝑡𝑝
𝑇𝑃} represents the probability output of true positives and the 
corresponding true label vector is {𝑇𝑡𝑝
1 , 𝑇𝑡𝑝
2 , ⋯ , 𝑇𝑡𝑝
𝑇𝑃}. The similarity of true positives 𝑇𝑃𝑠𝑖𝑚 is 
defined as: 
𝑇𝑃𝑠𝑖𝑚 = ∑ 𝑠𝑖𝑚(𝑃𝑡𝑝
𝑘 , 𝑇𝑡𝑝
𝑘 )𝑇𝑃𝑘=1 = ∑
2 ∑ 𝑃𝑡𝑝,𝑗
𝑘 𝑇𝑡𝑝,𝑗
𝑘2
𝑗=1
∑ (𝑃𝑡𝑝,𝑗
𝑘 )
2
+∑ (𝑇𝑡𝑝,𝑗
𝑘 )
2
2
𝑗=1
2
𝑗=1
𝑇𝑃
𝑘=1 ,          (9) 
In gene mutation prediction, j=1 represents mutation, j=2 represents non-mutation, and 𝑃𝑘 
is the mutation probability. Also, 𝑃𝑡𝑝,1
𝑘 = 𝑃𝑘 , 𝑃𝑡𝑝,2
𝑘 = 1 − 𝑃𝑘 , 𝑇𝑡𝑝,1
𝑘 = 1,  and 𝑇𝑡𝑝,2
𝑘 = 0 . 
Therefore, equation (9) can be simplified as: 
𝑇𝑃𝑠𝑖𝑚 = ∑
𝑃𝑘
(𝑃𝑘)
2
−𝑃𝑘+1
𝑇𝑃
𝑘=1 ,                         (10) 
 Similarly, we define the similarity of true negatives 𝑇𝑁𝑠𝑖𝑚, false positives 𝐹𝑃𝑠𝑖𝑚, and false 
negatives 𝐹𝑁𝑠𝑖𝑚:  
𝑇𝑁𝑠𝑖𝑚 = ∑
1−𝑃𝑘
(𝑃𝑘)
2
−𝑃𝑘+1
𝑇𝑁
𝑘=1 ,                        (11) 
𝐹𝑃𝑠𝑖𝑚 = ∑
1−𝑝𝑘
(𝑃𝑘)
2
−𝑃𝑘+1
𝐹𝑃
𝑘=1 ,                         (12) 
𝐹𝑁𝑠𝑖𝑚 = ∑
𝑝𝑘
(𝑝𝑘)
2
−𝑝𝑘+1
𝐹𝑁
𝑘=1 .                         (13) 
Then, 𝑓𝑠𝑖𝑚_𝑠𝑒𝑛, 𝑓𝑠𝑖𝑚_𝑠𝑝𝑒 are calculated as: 
𝑓𝑠𝑖𝑚_𝑠𝑒𝑛 =
𝑇𝑃𝑠𝑖𝑚
𝑇𝑃𝑠𝑖𝑚+𝐹𝑁𝑠𝑖𝑚 
, 𝑓𝑠𝑖𝑚_𝑠𝑝𝑒 =
𝑇𝑁𝑠𝑖𝑚
𝑇𝑁𝑠𝑖𝑚+𝐹𝑃𝑠𝑖𝑚 
,                (14) 
Our aim was to maximize the two similarity-based objective functions simultaneously as: 
𝑓𝑠𝑖𝑚 = max
𝒘,𝑹
(𝑓𝑠𝑖𝑚_𝑠𝑒𝑛, 𝑓𝑠𝑖𝑚_𝑠𝑝𝑒).                   (15) 
Once training is finished, the Pareto-optimal solution set is generated, and the best model 
parameters and weights are selected based on the clinical needs. In the following subsection, 
we describe a new algorithm that was developed to solve the similarity-based multi-objective 
optimization problem.  
2.3. Similarity-based multi-objective optimization (SMO) algorithm 
Multi-objective evolutionary algorithms (MOEA) have demonstrated the superior 
performance for multi-objective optimization (Deb, 2001). Based on MOEA, we have proposed 
an iterative multi-objective immune algorithm (IMIA), which adopts the traditional sensitivity 
and specificity as the optimized objective functions (Zhou et al, 2017). Based on IMIA, we 
propose a new SMO algorithm. The major difference between IMIA and SMO is that the 
reliability is measured through similarity between output probability and label vector during 
the training process. Additionally, weighting coefficients needs to be optimized in SMO. For 
conciseness, we just gave a brief description of SMO and focused on the difference between 
SMO and IMIA. For a full and detailed algorithm, please refer to our previous paper (Zhou et 
al, 2017).    
As IMIA, SMO consists of the 7 steps: initialization, cloning, mutation, deletion, solution 
updating, termination and best solution selection. In initialization, model parameters R and 
weights w were both initialized. We generated the initial solution set 𝐷(𝑡) =
{𝑑1, ⋯ , 𝑑𝐻}( 𝑡 = 0) randomly, 𝑑𝑖(𝑖 = 1, ⋯ , 𝐻) is a particular solution, H is the number of 
solutions, and 𝑡 is the number of generation. In cloning step, there is a big difference. In SMO, 
new similarity-based proportional cloning operation was proposed, where the solution with 
higher similarity was reproduced multiple times. Specifically, the clonal time 𝐶𝐿𝑇𝑖 for each 
solution is calculated as: 
𝐶𝐿𝑇𝑖 = ⌈𝑛𝑐 ×
𝑠𝑖𝑚(𝑑𝑖)
∑ 𝑠𝑖𝑚(𝑑𝑖)
𝐻
𝑖=1
⌉,                          (15) 
where 𝑛𝑐 is the expected value of the clonal solution set and ⌈ ⌉ is the ceiling operator. 
The similarity measure for solution 𝑑𝑖  denoted by 𝑠𝑖𝑚(𝑑𝑖) is calculated as: 
𝑠𝑖𝑚(𝑑𝑖) = ∑
2 ∑ 𝑃𝑗
𝑘𝑇𝑗
𝑘2
𝑗=1
∑ (𝑃𝑗
𝑘)
2
+∑ (𝑇𝑗
𝑘)
2
2
𝑗=1
2
𝑗=1
𝐾
𝑘=1 ,                    (16) 
where 𝐾 is the number of training samples and 𝑇𝑗
𝑘 is the label vector.  
   The mutation and deletion in SMO are the same as those in IMIA. In this paragraph, 
“mutation” refers to the operation performed on the cloned solution set, not the gene 
mutation. The mutation probability threshold 𝑀𝑃  is determined empirically and an 
operation probability 𝑅𝑃𝑖  is generated randomly. If  𝑅𝑃𝑖 > 𝑀𝑃 , a mutation operation is 
performed in which a new solution 𝑑𝑖
𝑚 was generated randomly and replace the original 
solution 𝑑𝑖 . Then, a newly generated mutated solution set 𝑀(𝑡)  and solution set 𝐷(𝑡) 
constitute the new solution set denoted by 𝐹(𝑡). Same solutions in 𝐹(𝑡) were removed and 
a new solution set 𝐷𝐹(𝑡) is generated. 
 In solution updating step of SMO, the aim is to select 𝐻  solutions from 𝐷𝐹(𝑡)  to 
maintain the population size. For each solution, we can obtain the similarities based on the 
probability outputs of all the training samples, according to equation (16). 𝑓𝑠𝑖𝑚_𝑠𝑒𝑛  and 
𝑓𝑠𝑖𝑚_𝑠𝑝𝑒 can also be calculated according to equation (14). Using the MOEA (Deb, 2001; Deb 
et al, 2002) , we selected H solutions. Unlike most traditional MOEAs, the solution in 𝐷𝐹(𝑡) 
is sorted according to the similarity of each solution. Then, the new solution set 𝑈𝐷(𝑡) is 
generated. 
    When t reaches the maximal number of generations 𝐺𝑚𝑎𝑥, the algorithm terminates. 
The best solution is selected from the Pareto-optimal solution set 𝑈𝐷(𝐺𝑚𝑎𝑥) according to 
clinical needs. We selected the best solution according to the similarity-based sensitivity, 
specificity, and AUC. First, the thresholds Tsim_sen and T sim_spe are determined for similarity-
based sensitivity and specificity according to clinical needs. Second, for each solution 𝑑𝑖  in 
𝑈𝐷(𝐺𝑚𝑎𝑥), we calculate its similarity-based sensitivity 𝑓𝑠𝑖𝑚_𝑠𝑒𝑛
𝑖  and specificity 𝑓𝑠𝑖𝑚_𝑠𝑝𝑒
𝑖 . If 
𝑓𝑠𝑖𝑚_𝑠𝑒𝑛
𝑖 >  𝑇𝑠𝑖𝑚_𝑠𝑒𝑛 and 𝑓𝑠𝑖𝑚_𝑠𝑝𝑒
𝑖 >  𝑇𝑠𝑖𝑚_𝑠𝑝𝑒, 𝑑𝑖  is selected as a candidate solution. Third, 
we select the solution with the highest AUC from the candidate solutions as our final solution. 
2.4 Training and testing procedure of the MCMO model 
The training process mainly consists of three stages: feature calculation, feature selection, and 
predictive model construction. To achieve optimal performance for each classifier, we adopted 
our multi-objective feature selection method (Zhou et al, 2017). After selecting the features 
for each classifier, model parameters 𝑹𝑖 and weights 𝑤𝑖 (𝑖 = 1,2, … 𝑀) were trained. The 
workflow is illustrated in figure 3. 
   The testing process consists of three stages (figure 4). For a test sample, first, the features 
for each classifier are selected; second, each classifier outputs a probability 𝑃𝑖
𝑗  (𝑗 = 1,2;  𝑖 =
1,2, … 𝑀); third, the final mutation probability 𝑃𝑓𝑖𝑛
𝑗
 is obtained by combining all 𝑃𝑖
𝑗
 and 𝑤𝑖 
using the ER approach. Then the label can be determined. 
   We used six different classifiers in the MCMO model, including support vector machine 
(SVM) (Keerthi and Lin, 2003), logistic regression (LR) (Freedman, 2009), discriminant analysis 
(DA) (Hastie and Tibshirani, 1996), decision tree (DT) (Breiman, 2001), K-nearest-neighbor 
(KNN) (Keller et al, 2012), and naive Bayesian (NB) (Goldszmidt and Moises, 1997). Since SVM 
has two model parameters and other classifiers use default parameters, we train eight 
parameters {𝑅𝑆𝑉𝑀_1, 𝑅𝑆𝑉𝑀_2, 𝑤1, … 𝑤6 }for the predictive model. 
 Figure 3. Training process of MCMO predictive model. 
 
Figure 4. Testing process using MCMO predictive model. 
3. Results 
3.1 Experimental setup 
In MCMO, the population number H and the maximal generation number 𝐺𝑚𝑎𝑥 were both 
set to 100. In the clone operation, 𝑛𝑐 was set to 200. In the mutation operation, the mutation 
probability MP was set to 0.9. The proposed MCMO predictive model was compared to three 
types of predictive model: (1) models with single classifiers; (2) models with different multi-
objective optimization; (3) models with different fusion strategies. Because multi-objective 
optimization is better than the single-objective model (Zhou et al, 2017), we did not compare 
our proposed model to models with single-objective optimization. Area under the receiver 
operating characteristic curve (AUC), accuracy, sensitivity, specificity, similarity-based 
sensitivity (Sim-sensitivity), and similarity-based specificity (Sim-specificity) were used for 
evaluating the model performance. 
   In our study, eight parameters in the predictive model need to be trained and our dataset 
has 57 cases. We adopted two-fold cross-validation in this work. Cross-validation is a widely 
used model validation technique which can test the model’s ability to predict new data that 
were not used in training, in order to flag problems like overfitting (Kohavi, 1995). One round 
of cross-validation involves partitioning a sample of data into complementary subsets. In our 
work, two-fold cross-validation was used, where for each round, half cases (training set) were 
selected randomly for training and the other half cases (validation set) were used for validation, 
then reverse. To reduce variability caused by subset partition, ten rounds of two-fold cross-
validation were performed for each model, and the validation results were averaged over the 
10 rounds to give an estimate of the model’s predictive performance (table 3). Prediction 
results of AUC, accuracy, sensitivity and specificity of training set were also listed in table 3. 
The prediction accuracy of training set is higher than that obtained from the validation set, 
which is considered as normal for a machine learning algorithm. On the other hand, the 
accuracies of the training set are not close to 1 and the predictive results on the validation set 
are acceptable. In the remaining of the paper, all the prediction results were from the 
validation set. 
Table 3. Results of MCMO prediction models (training set vs. validation set) 
Gene Data set AUC Accuracy Sensitivity Specificity 
VHL 
Training set 0.960.02 0.910.01 0.930.02 0.880.02 
Validation set 0.880.01 0.810.02 0.790.04 0.860.02 
PBRM1 
Training set 0.950.01 0.900.03 0.870.03 0.920.02 
Validation set 0.860.02 0.780.02 0.750.02 0.800.02 
BAP1 
Training set 0.970.01 0.920.01 0.90.03 0.920.01 
Validation set 0.930.02 0.900.02 0.870.02 0.900.03 
 
3.2 Selected features for the three genes 
We obtained the classifier-specific feature subset and summarized the features selected by all 
(six) classifiers (table 4). Statistics using the unpaired T test were also listed. The feature 
selected by all classifiers indicates that the feature is important to predict mutation. P-value 
smaller than 0.05 indicated significant differences between presence and absence of 
mutations. However, four selected features (Minimum, Contrast, Variance and Sum variance) 
for the PBRM1 gene and three selected features (Variance, Sum average and Sum variance) 
for the BAP1 gene had P-values greater than 0.05. Because we selected the optimal features 
according to multi-objective model, using the AUC as the figure of metric, these selected 
features did not necessarily have P-values smaller than 0.05. Example boxplots were plotted 
to show the potential of a single feature for differentiating between the presence and absence 
of mutations (figure 5).  
Table 4. Selected features by all (six) classifiers for VHL, PBRM1 and BAP1 genes. 
 Geometry (P-value) Intensity (P-value) Texture (P-value) 
VHL Mean (0.020) Kurtosis (0.002)  
PBRM1  Minimum (0.088) Contrast (0.085) 
  Mean (0.020) Maximum probability (0.030) 
  Median (0.041) Variance (0.162) 
  Skewness (0.042) Sum variance (0.168) 
  Kurtosis (0.005)  
BAP1 Size_X (0.006) Sum (0.048) Homogeneity (0.023) 
   Variance (0.171) 
   Sum average (0.159) 
   Sum variance (0.168) 
Two intensity features including Mean and Kurtosis are the most frequently selected 
features in VHL gene prediction. A histogram with a more elongated tail indicates smaller 
Kurtosis. A tumor with smaller Kurtosis is more likely to carry a VHL mutation (figure 5(a) and 
figure 6). For the PBRM1 gene prediction, nine features from intensity and texture features, 
were most frequently selected. A boxplot of the Mean is illustrated in figure 5(b). Five features 
were selected as the most prominent contributors in BAP1. Four texture features were 
selected as follows: Homogeneity, Variance, Sum average, and Sum variance. A lower similarity 
in intensity between a voxel and its neighbors led to higher Variance and Sum variance. A less 
uniform or more focal intensity distribution led to reduced Homogeneity. Therefore, larger 
Variance, and smaller Homogeneity were associated with the likelihood that a tumor carried 
a BAP1 mutation. Boxplot of Homogeneity is illustrated in figure 5(c). 
   
(a)                           (b)                        (c) 
Figure 5. Boxplots for (a) Kurtosis (VHL), (b) Mean (PBRM1), and (c) Homogeneity (BAP1). 
   
(a)                                       (b) 
   
(c)                                       (d) 
Figure 6. Kurtosis in tumor CT images. (a) A tumor without VHL mutation, (b) Histogram, with kurtosis= 
26.57 (Z-score= 1.92), (c) A tumor with VHL mutation, (d) Histogram with kurtosis= 7.17 (Z-score= -1.33). 
 
It is noted that one single feature may not achieve accurate predictive results. For each 
classifier, a feature set is necessary. For KNN classifier, a feature set consisting of 12 features 
(Volume, Size_P3, Minimum, Maximum, Mean, Sum, Variance, Standard deviation, Kurtosis, 
Cluster shade, Energy, Inverse difference) was selected to predict VHL mutation; while for LR 
classifier, a feature set consisting of 19 features (Volume, Size_Z, Size_P2, Roundness, Surface 
area, Mean, Standard deviation, Skewness, Kurtosis, Contrast, Dissimilarity, Energy, Entropy, 
Homogeneity, Sum entropy, Information measure of correlation_1, Information measure of 
correlation_2, Inverse difference, Inverse difference normalized) was selected to predict VHL 
mutation.   
3.3 Performance evaluation of MCMO vs. single classifiers  
MCMO yielded better AUC, accuracy, sensitivity, and specificity results than other single 
classifiers (table 5). The prediction accuracy of MCMO is 0.81, 0.78, and 0.90 for VHL, PBRM1, 
and BAP1 genes, respectively, with AUC >= 0.86 sensitivity > =0.75 and specificity > =0.80. 
MCMO yielded better results than other single classifiers. KNN is the best single classifier for 
the VHL and PBRM1 genes, with specificities of 0.66 and 0.62, respectively. MCMO can achieve 
specificities of 0.86 and 0.80 for VHL and PBRM1 genes, respectively. SVM and DA achieved 
similar results for the BAP1 gene, which are better than other single classifiers, but sensitivities 
were only 0.57 and 0.63, respectively; the sensitivity obtained by MCMO was 0.87. Some single 
classifiers achieved higher sensitivities for the VHL gene, but the corresponding specificities 
were poor. MCMO achieved the highest AUC and accuracy with balanced sensitivities and 
specificities (difference < 0.1). Also, MCMO is a stable predictive model because its standard 
deviations are much smaller than those of the single classifiers. 
3.4 Comparative study of objective functions 
One group of the Pareto-optimal solution set and the selected final solution in SMO is shown 
in figure 7. As described in section 2.3, the best solution was selected according to the 
similarity-based sensitivity, specificity (equation (14)), and AUC. First, thresholds Tsim_sen and T 
sim_spe were determined for similarity-based sensitivity and specificity based on clinical needs. 
In this study, the thresholds Tsim_sen and T sim_spe are both 0.9. The selected candidate solutions 
were included within the red rectangle and the selected final solution (highest AUC) was 
marked in red.  
We evaluated the performance of our MCMO by comparing it to the iterative multi-objective 
immune algorithm (IMIA), which adopts the traditional sensitivity and specificity as the 
optimized objective functions (Zhou et al, 2017) (figure 8). The two methods were compared 
with the unpaired T test at a significance level 0.05 (table 6). Results were similar based on 
AUC, accuracy, sensitivity and specificity (P-value> 0.05). For VHL and PBRM1 genes, SMO 
achieved a little higher AUCs. For all three genes, SMO achieved significantly higher similarity 
scores (P-value <= 0.01), indicating that these results are more reliable. For the prediction 
result with higher AUC, the difference of 𝑓𝑠𝑖𝑚_𝑠𝑒𝑛 or 𝑓𝑠𝑖𝑚_𝑠𝑝𝑒 between SMO and IMIA is small. 
For example, for the BAP1 gene, the difference of 𝑓𝑠𝑖𝑚_𝑠𝑒𝑛 and that of 𝑓𝑠𝑖𝑚_𝑠𝑝𝑒 are 0.03 and 
0.02. However, for the prediction result with lower AUC, such as for the PBRM1 gene, the 
difference of 𝑓𝑠𝑖𝑚_𝑠𝑒𝑛 is 0.13 and that of 𝑓𝑠𝑖𝑚_𝑠𝑝𝑒 is 0.07. 
 
Table 5. Results of different prediction models (MOMC vs. single classifier) 
Gene Classifier AUC Accuracy Sensitivity Specificity 
VHL 
SVM 0.710.06 0.690.05 0.880.07 0.370.11 
NB 0.330.14 0.670.05 0.840.10 0.360.16 
LR 0.730.04 0.710.05 0.730.05 0.670.09 
KNN 0.800.04 0.780.03 0.840.04 0.660.08 
DT 0.670.06 0.680.07 0.710.08 0.610.11 
DA 0.710.05 0.660.05 0.680.11 0.640.10 
MCMO 0.880.01 0.810.02 0.790.04 0.860.02 
PBRM1 
SVM 0.680.06 0.630.06 0.520.14 0.700.06 
NB 0.410.09 0.580.05 0.520.11 0.620.08 
LR 0.620.10 0.630.09 0.520.14 0.690.09 
KNN 0.670.10 0.640.10 0.650.16 0.620.11 
DT 0.520.08 0.540.07 0.440.10 0.600.10 
DA 0.590.07 0.590.06 0.540.10 0.620.09 
MCMO 0.860.02 0.780.02 0.750.02 0.800.02 
BAP1 
SVM 0.800.07 0.810.03 0.570.11 0.850.04 
NB 0.740.11 0.020.02 0.240.0 0.880.02 
LR 0.690.08 0.810.03 0.540.21 0.840.04 
KNN 0.720.06 0.800.05 0.570.10 0.830.06 
DT 0.540.09 0.810.06 0.240.18 0.890.08 
DA 0.820.08 0.800.05 0.630.20 0.820.04 
MCMO 0.930.02 0.900.02 0.870.02 0.900.03 
 
 
 
(a) 
 (b) 
 
(c) 
Figure 7. Pareto-optimal solution set (green rhombus), the green rhombus within the red rectangle are 
candidate solutions which satisfy 𝑓𝑠𝑖𝑚_𝑠𝑒𝑛 >  𝑇𝑠𝑖𝑚_𝑠𝑒𝑛 and 𝑓𝑠𝑖𝑚_𝑠𝑝𝑒 >  𝑇𝑠𝑖𝑚_𝑠𝑝𝑒. 𝑇𝑠𝑖𝑚_𝑠𝑒𝑛 = 𝑇𝑠𝑖𝑚_𝑠𝑝𝑒 =
0.9. The best solution selected for SMO is indicated by the red rhombus. (a) VHL; (b) PBRM1; (c) BAP1. 
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(c) 
Figure 8 . Results of using different objective functions. (a) VHL; (b) PBRM1; (c) BAP1. 
Table 6. Results of P-values compared between SMO and IMIA  
Gene AUC Accuracy Sensitivity Specificity Sim-sensitivity Sim-specificity 
VHL 0.116 0.449 0.226 0.206 0.003 0.0002 
PBRM1 0.412 0.690 0.355 0.355 <0.0001 <0.0001 
BAP1 0.574 0.536 0.330 0.472 0.01 0.007 
3.5 Comparative study of fusing method 
We used the ER approach (equation (4)) for fusing the output of different classifiers. The classic 
weighted fusion (WF) method is used for comparison, as: 
𝑃 =  ∑ 𝑃𝑖𝑤𝑖
𝑀
𝑖=1                              (17) 
where 𝑃𝑖  is the individual classifier output probability and 𝑤𝑖 is the relative weight. SMO is 
used in both fusion strategies, and the comparative results are shown in figure 9. The two 
methods were compared with the unpaired t test at a significance level 0.05 (table 7). For VHL 
and PBRM1 genes, the ER approach achieved higher AUCs (P-value < 0.05). Also, sim-sensitivity 
and sim-specificity in ER are higher than WF (P-value <= 0.02), which indicates that more 
reliable results can be obtained when using ER fusion. 
 
 (a) 
 
(b) 
 
(c) 
Figure 9. Results of using different fusion strategies (ER vs. WF). (a) VHL; (b) PBRM1; (c) BAP1. 
Table 7. Results of P-values compared between ER and WF  
Gene AUC Accuracy Sensitivity Specificity Sim-sensitivity Sim-specificity 
VHL 0.021 0.083 0.760 0.018 0.007 <0.0001 
PBRM1 0.0001 0.244 0.306 0.492 0.04 0.02 
BAP1 0.882 0.045 0.330 0.074 0.02 0.0009 
 
4. Discussion  
The study of the association between diagnostic imaging features and mutations is a first 
critical step in the radiogenomics of ccRCC (Kuo and Yamamoto, 2011). While the genomic 
landscape of ccRCC is first characterized by the loss of VHL function, recent advances in cancer 
genome sequencing have identified additional, prognostically significant mutations. Two 
hypothesis-generating studies indicated the potential association between individual CT 
features and mutations of the VHL gene, and also mutations in the PBRM1, BAP1, SETD2 and, 
KDM5C genes (Karlo et al, 2014; Shinagare et al, 2015). The CT features identified by the 
radiologists were primarily morphological (e.g. necrosis, ill or well defined margins, renal vein 
invasion). In contrast, all of our features were quantitative descriptors extracted from the 
contoured tumor image. The feature extraction was automated, eliminating subjectivity and 
improving reproducibility.  
The most frequently selected features varied depending on the gene. The most frequently 
selected features of the VHL gene were intensity features (Mean and Kurtosis), which 
described the mean values and intensity distribution in tumor volume. Intensity and texture 
features were found to be important in the PBRM1 predictive model. The most selected 
features of PBRM1 consisted of five intensity features that measured the intensity distribution 
in tumor volume, and four texture features that measured the local differences within an 
image. Karlo et al (2014) reported that nodular, heterogeneous enhancement and visibility of 
intratumoral blood vessels in tumors were more common among ccRCCs with underlying VHL 
mutations. Also, investigators found an association between a well-defined tumor margin and 
the VHL mutation, and an association between solid ccRCC and mutations in VHL and PBRM1. 
However, Shinagare et al (2015) did not observe any imaging characteristics associated with 
PBRM1 and VHL mutations. Because both evaluations were subjective and their features were 
morphological, we were unable to directly compare our quantitative results with those 
morphological features. 
The most frequently selected features of BAP1 consisted of one geometry feature, one 
intensity feature, and four texture features. Texture features were the most prominent 
contributors in the BAP1 predictive model. In a study by Shinagare et al (2015), the BAP1 
mutation was found to be associated with ill-defined tumor margins and calcification. We did 
not study tumor margins because they are not a quantitative feature. However, the presence 
of calcification may be associated with selected features such as Homogeneity and Variance. 
We proposed a MCMO radiogenomics model that predicts gene mutations in ccRCC. Multi-
classifier models can fully use information extracted by different classifiers and potentially 
improve prediction accuracy. We used all six different classifiers without considering the 
performance of individual classifiers. In future work, we will test the performance of single 
classifiers, and remove those with lower performance for the multi-classifier model. SVM and 
NB results for the VHL gene were found to be poor (table 5), therefore eliminating them and 
using LR, KNN, DT and DA for fusion may improve prediction results.  
Both similarity-based sensitivity and specificity were considered simultaneously as the 
objects that guided construction of the predictive model. For the first time, we propose 
reliable outcome prediction, which refers to maximizing the similarity of output probability 
and true label (probability is 1). Higher similarity means higher reliability. We designed 
similarity-based sensitivity and specificity as optimized objective functions, which differ from 
traditional ones. Moreover, an SMO algorithm was developed to train the model to increase 
accuracy and confidence of predictive results. Compared with our previous IMIA method, 
similarity was adopted as a non-dominated sorting criterion upon updating the solution set. 
Also, the solution with higher similarity was kept. These findings indicate that the prediction 
results are more reliable (higher 𝑓𝑠𝑖𝑚_𝑠𝑒𝑛 and 𝑓𝑠𝑖𝑚_𝑠𝑝𝑒) when using our model. As for the 
fusion strategy, the ER approach is better than the classic WF in terms of similarity-based 
optimization. SMO algorithm and ER approach both contribute to reliability increase.  
Our study presents a number of limitations. First, the number of patients used in our study 
is relatively small. In our model, eight parameters (2 parameters of SVM and 6 weights) need 
to be estimated and two-fold cross-validation were used. While two-fold cross-validation 
results showed that our model achieved satisfactory results, a larger dataset and multi-
classifier fusion could help to reduce the potential risk of overfitting (Dietterich, 2000). In a 
future work, we can apply this MCMO model in different classification where dataset of larger 
size is available. Second, recent advances in genetics have led to the identification of several 
mutations associated with ccRCC, including those involving the VHL, BAP1, PBRM1, SETD2, 
MUC4 and KDM5C genes. The genomic information of all six genes were available for the 24 
patients in TCGA/TCIA data collection. However, genomic information of the three genes 
(SETD2, MUC4 and KDM5C) was not available for most of the 33 UTSW cases used in the 
present study. Thus, we only considered VHL, PBRM1 and BAP1 genes in this work. Third, the 
feature stability was not addressed in the current study. Our patient data was acquired by 
different CT scanners at different institutions with different protocols, which resulted in 
differences in pixel size and slice thickness, while the differences of scanner and protocol have 
influence on feature calculations (Mackin et al, 2015). Additionally, tumor delineation was 
conducted by one physician and reviewed by another physician in this study. This could also 
introduce inter-observer variability in tumor delineation. Standardization of image acquisition 
protocols, automatic segmentation or consensus contours from more physicians may further 
improve the performance of the model developed in this work.  
5. Conclusion 
We proposed a multi-classifier multi-objective (MCMO) radiogenomics model that predicts 
VHL, PBRM1, and BAP1 gene mutations in ccRCC using quantitative CT feature set. Using our 
feature selection strategy and model, we achieved a predictive AUC greater than 0.85 for all 
three genes. Compared to single classifiers, multi-classifiers fused through ER and trained by 
developed SMO algorithm can greatly improve prediction accuracy and reliability. In MCMO, 
the concept of reliable outcome prediction was first proposed and applied to the optimization 
procedure, generating more reliable results. The MCMO model should not only be applied to 
radiogenomics, but also to solving other outcome prediction problems in medicine. 
 
Acknowledgement 
This work was supported in part by the American Cancer Society ACS-IRG-02-196 (J. Wang), 
the US National Institutes of Health P50CA196516 (J. Brugarolas, P. Kapur, I. Pedrosa) and 
R01CA154475 (I. Pedrosa), and the National Natural Science Foundation of China 61401349 
(X. Chen) and 61571359 (X. Mou). The authors thank Dr. Damiana Chiavolini for editing the 
manuscript.  
 
 
Aerts H J, Velazquez E R, Leijenaar R T, Parmar C, Grossmann P, Carvalho S, Bussink J, Monshouwer R, 
Haibe-Kains B and Rietveld D 2014 Decoding tumour phenotype by noninvasive imaging using 
a quantitative radiomics approach Nat. Commun. 5 4006 
Breiman L 2001 Random Forests Mach. Learn. 45 5-32 
Cancer Genome Atlas Research Network 2013 Comprehensive molecular characterization of clear cell 
renal cell carcinoma Nature 499 43-9 
Carles J, Chirivella I, Climent M Á, Gallardo E, Del Alba A G, Maroto J P, Mellado B and Del Muro F X G 
2012 Evaluation of patients with metastatic renal cell carcinoma after failure of first-line 
treatment Cancer Metastasis Rev. 31 S3-S9 
Cheadle C, Vawter M P, Freed W J and Becker K G 2003 Analysis of microarray data using Z score 
transformation J. Mol. Diagn. 5 73-81 
Clark K V B, Smith K, Freymann J, Kirby J, Koppel P, Moore S, Phillips S, Maffitt D, Pringle M, Tarbox L, 
Prior F 2013 The Cancer Imaging Archive (TCIA): Maintaining and Operating a Public 
Information Repository J. Digit. Imaging 26 1045-57 
Dalgliesh G L, Furge K, Greenman C, Chen L, Bignell G, Butler A, Davies H, Edkins S, Hardy C and Latimer 
C 2010 Systematic sequencing of renal carcinoma reveals inactivation of histone modifying 
genes Nature 463 360-3 
Deb K 2001 Multi-Objective Optimization Using Evolutionary Algorithms vol 16 (New York: Wiley) 
Deb K, Pratap A, Agarwal S and Meyarivan T 2002 A fast and elitist multiobjective genetic algorithm: 
NSGA-II IEEE T. Evolut. Comput. 6 182-97 
Dietterich T G 2000 Ensemble methods in machine learning International Workshop on Multiple 
classifier systems. Springer, Berlin, Heidelberg. 1-15 
Duns G, van den Berg E, van Duivenbode I, Osinga J, Hollema H, Hofstra R M and Kok K 2010 Histone 
methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell 
carcinoma Cancer Res. 70 4287-91 
Freedman D A 2009 Statistical Models: Theory and Practice (Cambridge, England: Cambridge University 
Press) 
Gerlinger M, Horswell S, Larkin J, Rowan A J, Salm M P, Varela I, Fisher R, McGranahan N, Matthews N 
and Santos C R 2014 Genomic architecture and evolution of clear cell renal cell carcinomas 
defined by multiregion sequencing Nat. Genet. 46 225-33 
Gerlinger M, Rowan A J, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart 
A and Tarpey P 2012 Intratumor heterogeneity and branched evolution revealed by multiregion 
sequencing N. Engl. J. Med. 366 883-92 
Gevaert O, Echegaray S, Khuong A, Hoang C D, Shrager J B, Jensen K C, Berry G J, Guo H H, Lau C and 
Plevritis S K 2017 Predictive radiogenomics modeling of EGFR mutation status in lung cancer 
Sci Rep 7 41674 
Gnarra J R, Tory K, Weng Y, Schmidt L, Wei M H, Li H, Latif F, Liu S, Chen F and Duh F M 1994 Mutations 
of the VHL tumour suppressor gene in renal carcinoma Nature Genetics 7 85-90 
Goldszmidt and Moises 1997 Bayesian Network Classifiers Mach. Learn. 29 131-63 
Guo G, Gui Y, Gao S, Tang A, Hu X, Huang Y, Jia W, Li Z, He M and Sun L 2012 Frequent mutations of genes 
encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell 
carcinoma Nat. Genet. 44 17-9 
Hakimi A A, Chen Y-B, Wren J, Gonen M, Abdel-Wahab O, Heguy A, Liu H, Takeda S, Tickoo S K and Reuter 
V E 2013 Clinical and pathologic impact of select chromatin-modulating tumor suppressors in 
clear cell renal cell carcinoma Eur. Urol. 63 848-54 
Haralick R M, Shanmugam K and Dinstein I H 1973 Textural features for image classification IEEE Trans. 
Syst. Man Cyber SMC-3 610-21 
Hastie T and Tibshirani R 1996 Discriminant Analysis by Gaussian Mixtures J. Roy. Stat. Soc. 58 155-76 
Jaffe C C 2012 Imaging and genomics: is there a synergy? Radiology 264 329-31 
Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell W K, Xie X-J and Brugarolas J 
2013 Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell 
carcinoma: a retrospective analysis with independent validation Lancet Oncol. 14 159-67 
Karlo C A, Di Paolo P L, Chaim J, Hakimi A A, Ostrovnaya I, Russo P, Hricak H, Motzer R, Hsieh J J and Akin 
O 2014 Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging 
features and mutations Radiology 270 464-71 
Keerthi S S and Lin C-J 2003 Asymptotic behaviors of support vector machines with Gaussian kernel 
Neural Comput. 15 1667-89 
Keller J M, Gray M R and Givens J A 2012 A fuzzy K-nearest neighbor algorithm IEEE T. Syst. Man Cy. 
SMC-15 580-5 
Kohavi R 1995 A study of cross-validation and bootstrap for accuracy estimation and model selection 
International Joint Conference on Artificial Intelligence. Morgan Kaufmann Publishers Inc. 
1137-43. 
Kuo M D and Jamshidi N 2014 Behind the numbers: decoding molecular phenotypes with 
radiogenomics—guiding principles and technical considerations Radiology 270 320-5 
Kuo M D and Yamamoto S 2011 Next generation radiologic-pathologic correlation in oncology: Rad-Path 
2.0 Am. J. Roentgenol. 197 990-7 
Mackin D, Fave X, Zhang L, Fried D, Yang J, Taylor B, Rodriguezrivera E, Dodge C, Jones A K and Court L 
2015 Measuring CT scanner variability of radiomics features Investigative Radiology 50 757 
McGranahan N and Swanton C 2015 Biological and therapeutic impact of intratumor heterogeneity in 
cancer evolution Cancer Cell 27 15-26 
Motzer R J, Bacik J, Mariani T, Russo P, Mazumdar M and Reuter V 2002 Treatment outcome and survival 
associated with metastatic renal cell carcinoma of non–clear-cell histology J. Clin. Oncol. 20 
2376-81 
Motzer R J, Jonasch E, Agarwal N, Bhayani S, Bro W P, Chang S S, Choueiri T K, Costello B A, Derweesh I 
H and Fishman M 2017 Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in 
Oncology J Natl Compr Canc Netw 15 804-34 
Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A, Leng N, Pavía-Jiménez A, Wang S, Yamasaki T, Zhrebker L, 
Sivanand S and Spence P 2012 BAP1 loss defines a new class of renal cell carcinoma Nat. Genet. 
44 751-9 
Powles T and Albers P 2012 Management of favorable-risk patients with metastatic renal cell carcinoma: 
when to start and when to stop targeted therapy Clin. Genitourin. Cancer 10 213-8 
Reznek R H 2004 CT/MRI in staging renal cell carcinoma Cancer Imaging 4 S25-S32 
Rutman A M and Kuo M D 2009 Radiogenomics: creating a link between molecular diagnostics and 
diagnostic imaging Eur. J. Radiol. 70 232-41 
Sala E, Mema E, Himoto Y, Veeraraghavan H, Brenton J D, Snyder A, Weigelt B and Vargas H A 2017 
Unravelling tumour heterogeneity using next-generation imaging: radiomics, radiogenomics, 
and habitat imaging Clin. Radiol. 72 3-10 
Sauk S C, Hsu M S, Margolis D J, Lu D S, Rao N P, Belldegrun A S, Pantuck A J and Raman S S 2011 Clear 
cell renal cell carcinoma: multiphasic multidetector CT imaging features help predict genetic 
karyotypes Radiology 261 854-62 
Shinagare A B, Vikram R, Jaffe C, Akin O, Kirby J, Huang E, Freymann J, Sainani N I, Sadow C A and Bathala 
T K 2015 Radiogenomics of clear cell renal cell carcinoma: preliminary findings of The Cancer 
Genome Atlas–Renal Cell Carcinoma (TCGA–RCC) Imaging Research Group Abdom. Imaging 40 
1684-92 
Siegel R L, Miller K D and Jemal A 2017 Cancer Statistics, 2017 Ca-Cancer J. Clin. 67 7-30 
Smith K C K, Bennett W, Nolan T, Kirby J, Wolfsberger M, Moulton J, Vendt B, Freymann J 2016 Radiology 
Data from The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma (TCGA-KIRC) collection 
Stewartmerrill S B, Thompson R H, Boorjian S A, Psutka S P, Lohse C M, Cheville J C, Leibovich B C and 
Frank I 2015 Oncologic Surveillance After Surgical Resection for Renal Cell Carcinoma: A Novel 
Risk-Based Approach Journal of Urology 193 e650-e1 
Sung-Hyuk C 2007 Comprehensive Survey on Distance/Similarity Measures between Probability Density 
Functions International Journal of Mathematical Models & Methods in Applied Sciences 1 300-
7 
Valdes G, Solberg T D, Heskel M, Ungar L and Simone C B 2016 Using machine learning to predict 
radiation pneumonitis in patients with stage I non-small cell lung cancer treated with 
stereotactic body radiation therapy Phys. Med. Biol. 61 6105-20 
Varela I, Tarpey P, Raine K, Huang D, Ong C K, Stephens P, Davies H, Jones D, Lin M-L and Teague J 2011 
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal 
carcinoma Nature 469 539-42 
Wang Y, Yang J and Xu D L 2006 Environmental impact assessment using the evidential reasoning 
approach Eur. J. Oper. Res. 174 1885-913 
Yamamoto S, Maki D D, Korn R L and Kuo M D 2012 Radiogenomic analysis of breast cancer using MRI: 
a preliminary study to define the landscape Am. J. Roentgenol 199 654-63 
Yang J B and Xu D L 2002 On the evidential reasoning algorithm for multiple attribute decision analysis 
under uncertainty IEEE T. Syst. Man Cy. A 32 289-304 
Yang J B and Xu D L 2013 Evidential reasoning rule for evidence combination Artif. Intell. 205 1-29 
Zhou Z, Folkert M, Iyengar P, Westover K, Zhang Y, Choy H, Timmerman R, Jiang S and Wang J 2017 Multi-
objective radiomics model for predicting distant failure in lung SBRT Phys. Med. Biol. 62 4460 
 
 
